MedPath

A Safety Study of LY3372689 in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: LY3372689
Registration Number
NCT04106206
Lead Sponsor
Eli Lilly and Company
Brief Summary

This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3372689 or placebo and will remain in the study for up to eight weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Overtly healthy vasectomized male or a female who cannot get pregnant
  • Have a body mass index (BMI) of 18.5 to ≤30 kilograms per square meter (kg/m²)
  • Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
  • Have veins suitable for ease of blood sampling
Read More
Exclusion Criteria
  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
  • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo administered orally
LY3372689LY3372689LY3372689 administered orally
Primary Outcome Measures
NameTimeMethod
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug AdministrationBaseline through final follow-up at approximately Day 30

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Secondary Outcome Measures
NameTimeMethod
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3372689Day 1 postdose through Day 15

PK: Cmax of LY3372689

PK: Area Under the Concentration Versus Time Curve (AUC) of LY3372689Day 1 postdose through Day 15

PK: AUC of LY3372689

Trial Locations

Locations (1)

Covance

🇺🇸

Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath